Where Does Exact Sciences Corporation (EXAS) Rank When It Comes To Price-To-Earnings Ratio?


Exact Sciences Corporation (NASDAQ:EXAS) finished Wednesday with a subtraction of -$1.59 to close at $36.30, a downside of -4.20 percent. An average of 2,045,320 shares of common stock have been traded in the last five days. There was a fall of -$4.26 in the past week, and it reached a new high 1 time over the past 12 months. The last 20 days have seen an average of 2,082,325 shares traded, while the 50-day average volume stands at 2,154,794.

EXAS stock has increased by 0.95% in the last month. The company shares reached their 1-month lowest point of $34.16 on 09/01/22. With the stock rallying to its 52-week high on 01/18/22, shares of the company touched a low of $34.16 and a high of $107.00 in 52 weeks. It has reached a new high 2 times so far this year and lost -53.36% or -$41.53 in price. In spite of this, the price is down -66.07% from the 52-week high.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now.


Insider Transactions

48 days have passed since Exact Sciences Corporation (EXAS) last reported insider trading activity. Baranick Brian, who is Gen. Mgr., Precision Oncology, most recently acquired $984 shares at $47.12 per share on Aug 05. In this transaction, the insider spent $46,366. Director, Zanotti Katherine S, disposed of 4,608 shares at a price of $45.14 on Jul 26. The insider now owns more than $208,005 worth of shares. Prior to that, President and CEO Conroy Kevin T went on to Sale 7 shares at $40.75 each on Jul 01. An amount of $285 was transacted.

Valuation Metrics

Exact Sciences Corporation (EXAS) stock’s beta is 1.34. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 3.45, the price-to-book (PB) ratio at 1.99.

Financial Health

The quick ratio of Exact Sciences Corporation for the three months ended March 30 was 2.20, and the current ratio was 2.50, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.70 and a total debt to equity ratio of 0.70 for the quarter ending March 30. Its gross profit as reported stood at $1.31 billion compared to revenue of $1.77 billion.

Earnings Surprise

For the three-month period that ended March 30, Exact Sciences Corporation had $514.62 million in cash and short-term investments compared to $50.0 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$166.06 million in the quarter, while revenues were shrunk -6.53%. The analyst consensus anticipated Exact Sciences Corporation’s latest quarter earnings to come in at -$1.07 per share, but it turned out to be -$1.04, a 2.80% surprise. For the quarter, EBITDA amounted to -$98.88 million. Shareholders own equity worth $176.96 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Exact Sciences Corporation (EXAS) price momentum. RSI 9-day as of the close on 21 September was 36.57%, suggesting the stock is Neutral, with historical volatility in this time frame at 46.90%.

As of today, EXAS’s price is $38.54 -10.50% or -$4.26 from its 5-day moving average. EXAS is currently trading +1.06% higher than its 20-day SMA and -36.90% lower than its 100-day SMA. However, the stock’s current price level is -22.22% below the SMA50 and -52.60% below the SMA200.

The stochastic %K and %D were 41.74% and 54.01%, respectively, and the average true range (ATR) was 2.01. With the 14-day stochastic at 26.53% and the average true range at 2.11, the RSI (14) stands at 40.20%. The stock has reached -1.97 on the 9-day MACD Oscillator while the 14-day reading was at -1.01.

Analyst Ratings

Credit Suisse launched coverage on Exact Sciences Corporation (NASDAQ: EXAS) in its analyst report released on August 25, 2022. The firm assigned the stock an Outperform rating.


Please enter your comment!
Please enter your name here